Could a pill help restore speech in progressive aphasia?

NCT ID NCT07033481

Ongoing Symptom relief Sponsor: EIP Pharma Inc Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This study tests a drug called neflamapimod in 20 people with a language disorder called nonfluent variant primary progressive aphasia (nfvPPA). The goal is to see if the drug is safe and if it can improve language symptoms. Participants will receive either the drug or a placebo for a set period.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: neflamapimod
What this could lead to: If it works, this could point toward a treatment that eases language symptoms in people with primary progressive aphasia.
What could go wrong: This is a very small, early-phase study with only 20 participants. It is primarily testing safety, so it may not show clear benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NONFLUENT VARIANT PRIMARY PROGRESSIVE APHASIA (NFVPPA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aphasia brain disorder central nervous system disorder cognitive disorder frontotemporal dementia language disorder nervous system disorder neurodegenerative disease primary progressive aphasia progressive non-fluent aphasia psychiatric disorder Speech

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NONFLUENT VARIANT PRIMARY PROGRESSIVE APHASIA (NFVPPA)

Contacts and locations

Locations

Clinical Ageing Research Unit, Campus for Ageing and Vitality, Biomedical Research Building

Newcastle upon Tyne, NE4 5PL, United Kingdom
Columbia University

New York, New York, 10032, United States
Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
Northwestern Memorial Hospital

Chicago, Illinois, 60611, United States
The Ohio State University

Columbus, Ohio, 43221, United States
Windsor Research Unit, Fulbourn Hospital

Cambridge, CB21 5EF, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.